Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Belumosudil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 18/20 | 0.91 |
| ▸ | ROCK1 known ✓ | Q13464 | 9/20 | 0.91 |
| ▸ | CLK2 | P49760 | 1/20 | 0.91 |
| ▸ | BLK | P51451 | 1/20 | 0.91 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.91 |
| ▸ | STK3 | Q13188 | 1/20 | 0.91 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.91 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.91 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.91 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.91 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.55 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Belumosudil SCHEMBL29575654 | 0.96 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL878202 | 0.96 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL29361017 | 0.96 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL29364140 | 0.96 | ROCK2 (1.00) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL31151877 | 0.94 | ROCK2 (0.88) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL23777554 | 0.93 | ROCK2 (0.94) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL29362786 | 0.93 | ROCK2 (0.94) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| Belumosudil SCHEMBL30634521 | 0.93 | ROCK2 (0.94) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL877618 | 0.89 | ROCK2 (0.87) | ROCK2ROCK1CLK2BLKCSNK2A1 | |
| SCHEMBL877914 | 0.87 | ROCK2 (0.84) | ROCK2ROCK1CLK2BLKCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| US-10570123-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. | 2019-06-13 | — | — | US | disclosed |
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX INC (US) | 2018-03-15 | — | — | US | disclosed |
| US-9440961-B2 | Rho-kinase inhibitors and method of preparation | SURFACE LOGIX, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20150344464-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | KADMON CORPORATION, LLC | 2015-12-03 | — | — | US | disclosed |
| US-8916576-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20130131047-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8357693-B2 | Pharmacokinetically improved compounds | SURFACE LOGIX, INC. (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120202793-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC | 2012-08-09 | — | — | US | disclosed |
| WO-2012040499-A2 | METABOLIC INHIBITORS | SURFACE LOGIX, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| US-20100144707-A1 | Pharmacokinetically improved compounds | SURFACE LOGIX, LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2008054599-A2 | RHO KINASE INHIBITORS | SURFACE LOGIX, INC. (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072710-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-20190177311-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-20130131047-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-20150344464-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-20100144707-A1 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-10570123-B2 | Pharmacokinetically improved compounds | ROCK2, ROCK1, RHOT2 | ROCK2 1/4885ROCK1 2/4885CLK2 1983/4885 |
| US-20120202793-A1 | RHO KINASE INHIBITORS | ROCK2, ROCK1, RHOA | ROCK2 1/4885ROCK1 2/4885CLK2 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.